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T h e ne w e ngl a nd jou r na l o f m e dicine T he first surgical procedure performed specifically for weight loss took place in 1954. 1 Since then, bariatric procedures have become less invasive and safer, and insights regarding the beneficial metabolic effects of such procedures have led to additional indications for these procedures. Relatively short-term, randomized, controlled trials have investigated clinical outcomes in obese patients who had type 2 diabetes and had undergone a bariatric surgical procedure or had received intensive, nonsurgical therapies, such as lifestyle and pharmacologic interventions. [2] [3] [4] [5] [6] [7] [8] Although such trials have made important clinical contributions, large gaps remain in the understanding of the long-term benefits and risks of bariatric surgery.
This article addresses the durability of health benefits related to Roux-en-Y gastric bypass. The current study represents a long-term, observational, prospective study of Roux-en-Y gastric bypass in the United States with high follow-up rates. We compared changes in weight and the incidence and remission rates of type 2 diabetes, hypertension, and dyslipidemia in patients with severe obesity who underwent Roux-en-Y gastric bypass with respective findings in two groups of patients with severe obesity who did not undergo bariatric surgery.
Me thods

Study Design
This observational, prospective study was initiated in July 2000, and patients were followed through March 2016. Of the 1156 patients enrolled, 835 patients with severe obesity had visited a single bariatric surgical center (Rocky Mountain Associated Physicians, Salt Lake City) seeking Roux-en-Y gastric bypass. Of these patients, half (418 patients) proceeded with surgery (surgery group) and the remaining 417 patients did not undergo surgery, primarily because their insurance did not cover the procedure (nonsurgery group 1). In addition, a population-based sample of 321 adults with severe obesity who had not previously undergone bariatric surgery was recruited (nonsurgery group 2). 9 Participants were 18 to 72 years of age, had no history of alcohol or narcotics abuse, had not undergone bariatric surgery, and had not had gastric or duodenal ulcers, a myocardial infarction (in the previous 6 months), or active cancer (in the previous 5 years). Other selection criteria are noted in the Supplementary Appendix, available with the full text of this article at NEJM.org, or have been published previously. 10, 11 The study protocol was approved by the institutional review boards at the University of Utah and at Intermountain Healthcare, and written informed consent was obtained from each patient.
Follow-up results from the 2-year and 6-year clinical examinations have been reported previously. 11, 12 At each examination, data on medical history, lifestyle interventions, and medications were recorded, and clinical measurements were performed. After the baseline examination, patients in the surgery group underwent Roux-en-Y gastric bypass. 13 Participants in the two nonsurgery groups received no study-based intervention for weight loss, although they were free to seek such therapy.
Study End Points
The primary end points were the percentage of original weight lost and the incidence and remission rates of type 2 diabetes, hypertension, and dyslipidemia among the survivors at 12 years. Patients were considered to have type 2 diabetes if they met one or more of the following conditions: a fasting blood glucose level of at least 126 mg per deciliter (7.0 mmol per liter), a glycated hemoglobin level of at least 6.5%, or current use of any antidiabetic medication. Patients were considered to have hypertension if they had a blood pressure of at least 140/90 mm Hg while seated, if they reported current use of antihypertensive medication, or both. Patients were considered to have dyslipidemia if they met one or more of the following conditions: a fasting lowdensity lipoprotein cholesterol level of at least 160 mg per deciliter (4.1 mmol per liter), a highdensity lipoprotein cholesterol level of less than 40 mg per deciliter (1.0 mmol per liter), a triglyceride level of at least 200 mg per deciliter (2.3 mmol per liter), or current use of lipidlowering medication. Remission of the prevalentdisease end points at the follow-up examination was defined as the absence of disease according to the criteria above. Quality of life and mortality rate were assessed as secondary study end points (see the Supplementary Appendix).
examination was obtained from primary care providers, searches of electronic medical records from large health care databases, records from hospitals in Utah, and telephone interviews (Fig. 1) . The National Death Index was used to determine vital status and causes of death through 2014.
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Statistical Analysis
Biochemical and blood pressure variables that were known to be affected by certain medications were adjusted to their estimated premedication levels for patients who were receiving such medication during the course of the study, as described previously. 11 Covariates used for this adjustment included sex, age, baseline body-mass index, marital status, income, and educational level. Log transformations were applied to glucose levels, insulin levels, glycated hemoglobin levels, levels of insulin resistance as measured with the use of homeostatic model assessment, and triglyceride levels. Changes in each outcome variable were compared between the surgery group and each of the two nonsurgery groups after adjustment for the baseline level of the outcome variable and the six covariates. Logistic regression was used to analyze the betweengroup differences in the incidence and remission rates of type 2 diabetes, dyslipidemia, and hypertension. Data from the patients who had a prevalent disease at baseline were excluded from the analyses of incidence, and data only from the patients who had a prevalent disease at baseline were used for the analyses of remission rates. Adjustments for multiple comparisons were performed as described in the Supplementary Appendix. Because this was an observational study, the possibility of unmeasured confounding cannot be excluded. However, as detailed in the Supplementary Appendix, multiple issues related to study validity have been addressed. (134.9 to 150.8) † * The surgery group comprised patients with severe obesity who sought and underwent gastric bypass. Nonsurgery group 1 comprised patients with severe obesity who sought but did not undergo gastric bypass (primarily for insurance reasons). Nonsurgery group 2 comprised a population-based sample of adults with severe obesity who were randomly recruited in the study. At baseline, the sample sizes of the surgery group and nonsurgery groups 1 and 2 include data from all the patients examined. At the 12-year follow-up, the sample size for all the groups does not include data from the patients who died or were lost to follow-up. No adjustment of the confidence intervals or significance levels was performed for multiple comparisons. 
Clinical Data
Unadjusted mean baseline and 12-year values for the clinical variables are shown in Table 1 . For each of the two nonsurgery groups, results of analyses performed with and without data from surviving patients who later had bariatric surgery are reported. Values for the clinical variables at 2 years and at 6 years were reported previously, although additional 2-year and 6-year data from some patients were obtained at 12 years and were included in the current analysis.
11,12
The mean unadjusted change from baseline in body weight in the surgery group was −46. Table 2 shows the adjusted mean changes from baseline in the clinical variables at 12 years (12-year value minus baseline value). As with the unadjusted values, the adjusted values at 2 years and at 6 years were reported previously. 11, 12 The mean change from baseline in body weight in the surgery group was −45.0 kg (95% CI, −47.2 to −42.9; mean percent change, −35.0) at 2 years, −36.3 kg (95% CI, −39.0 to −33.5; mean percent change, −28.0) at 6 years, and −35.0 kg (95% CI, −38.4 to −31.7; mean percent change, −26.9) at 12 years; the mean change at 12 years in nonsurgery group 1 was −2.9 kg (95% CI, −6.9 to 1.0; mean percent change, −2.0), and the mean change at 12 years in nonsurgery group 2 was 0 kg (95% CI, −3.5 to 3.5; mean percent change, −0.9). Figure 2 further illustrates weight change after Roux-en-Y gastric bypass in individual patients from baseline to years 2, 6, and 12. Despite a wide variation in change in body weight across the sample, 360 of 387 patients (93%) in the surgery group maintained at least a 10% weight loss from baseline to year 12, 271 (70%) maintained at least a 20% weight loss, and 155 (40%) maintained at least a 30% weight loss. Only 4 of 387 patients (1%) in the surgery group had regained all their postsurgical weight loss. Patients in nonsurgery groups 1 and 2 who did not later undergo bariatric surgery had no significant changes from baseline to year 12 in weight, body-mass index, or waist circumference.
Incidence, Remission Rate, and Mortality Rate Table 3 shows that the 12-year incidence of type 2 diabetes was 3% (8 of 303 patients) in the surgery group, as compared with 26% (42 of 164 patients) in nonsurgery group 1 and 26% (47 of 184 patients) in nonsurgery group 2. The adjusted odds ratio for the incidence of type 2 diabetes in the surgery group versus nonsurgery group 1 was 0.08 (95% CI, 0.03 to 0.24; P<0.001), and the adjusted odds ratio in the surgery group versus nonsurgery group 2 was 0.09 (95% CI, 0.03 to 0.29; P<0.001). The incidence rates of hypertension and dyslipidemia were also significantly lower in the surgery group than in each of the two nonsurgery groups (Table 3 ).
In the surgery group, remission of type 2 diabetes was observed in 66 of 88 patients (75%) at 2 years, in 54 of 87 patients (62%) at 6 years, 11, 12 and in 43 of 84 patients (51%) at 12 years (Table 3) . Of the 62 patients in the surgery group who had initial remission at 2 years and had 12-year follow-up data, 69% remained free of type 2 diabetes at 12 years. When the remission rate of type 2 diabetes at 12 years in the surgery group was compared with that in the nonsurgery groups, the adjusted odds ratio for remission was 8.9 (95% CI, 2.0 to 40.0) for the surgery group versus nonsurgery group 1 and 14.8 (95% CI, 2.9 to 75.5) for the surgery group versus nonsurgery group 2 (P<0.001 for both comparisons) ( Table 3) . Successful remission of type 2 diabetes was strongly predicted by baseline medication status. Remission of type 2 diabetes at 12 years was observed in 16 of 22 patients in the surgery group (73%; 95% CI, 46 to 99) who had type 2 diabetes but had not been receiving antidiabetic medications at baseline, as compared with 24 of 43 patients with diabetes (56%; 95% CI, 35 to 77) who had been receiving only oral medications at baseline and 3 of 19 patients with diabetes (16%; 95% CI, −8 to 39) who had been receiving insulin (with or without additional oral antidiabetic medication) at baseline. The odds ratios for patients who had received oral medications only versus those who had received no medication and for patients who had received insulin versus those who had received no medication were both significant (P<0.001, and P = 0.007 for trend across the three medicationstatus groups). Among the patients who had type 2 diabetes both at baseline and at the 12-year follow-up, improvement was still evident, with a decreased mean (±SD) number of antidiabetic medications from baseline to 12 years in the surgery group (−0.3±1.4), as compared with increases in the mean numbers of antidiabetic medications from baseline to 12 years in nonsurgery group 1 (0.8±1.4, P = 0.002 by the KruskalWallis test) and in nonsurgery group 2 (1.1±1.3, P<0.001 by the Kruskal-Wallis test).
The remission rate of hypertension in the surgery group was significantly higher than the rate in nonsurgery group 1 (adjusted odds ratio, 5.1; 95% CI, 1.7 to 15.6; P<0.001) but was not significantly higher than the rate in nonsurgery group 2 (adjusted odds ratio, 2.4; 95% CI, 0.9 to 5.9) at 12 years. Furthermore, the remission rates of the three variables contributing to dyslipidemia (high-density lipoprotein cholesterol, lowdensity lipoprotein cholesterol, and triglycerides) were significantly higher in the surgery group than in each of the nonsurgery groups, with adjusted odds ratios varying from 3.3 (95% CI, 1.3 to 8.1) to 18.6 (95% CI, 2.8 to 124.2) ( Table 3) .
Details on all-cause and cause-specific mortality rates at the 12-year follow-up are provided in the Supplementary Appendix. There were 7 deaths by suicide (5 in the surgery group and 2 in nonsurgery group 1); both suicide deaths in nonsurgery group 1 occurred after the patients had undergone bariatric surgery.
Discussion
The 12-year results of this controlled, prospective study show that Roux-en-Y gastric bypass offered long-term durability of weight loss and was associated with fewer obesity-related coexisting conditions than among patients who did not undergo gastric bypass. The mean percent weight loss in the surgery group remained stable between 6 years (28.0% weight loss) and 12 years (26.9%). Furthermore, at 12 years, incident type 2 diabetes was still uncommon among patients who underwent Roux-en-Y gastric bypass, and the remission rate of type 2 diabetes also remained high. Remission of type 2 diabetes was much more likely if the Roux-en-Y gastric bypass occurred before the onset of treatment with insulin, presumably owing to the ability of partially viable beta cells to improve their function. Clinical variables related to metabolic health (glucose levels, glycated hemoglobin levels, systolic blood pressure, and lipid levels) as well as remission and incidence rates of both hypertension and dyslipidemia were significantly more favorable in the surgery group than in the nonsurgery groups.
Another published long-term, prospective, controlled study of bariatric surgery, the Swedish Obese Subjects (SOS) study, had a 13.4-year re- cruitment period. 15 Beginning in 1987, participants in the study underwent primarily vertical banded gastroplasty (which is no longer performed), although later in the recruitment process, Roux-en-Y gastric bypass was performed more often than vertical banded gastroplasty. By the end of the recruitment process, patients in the surgery group who underwent Roux-en-Y gastric bypass (265 patients) represented only 13.2% of the patients in the surgery group. 16, 17 In the SOS study, the Roux-en-Y gastric bypass group at 10 years (34 patients) had a weight change of −25%, 18 which is similar to the −26.9% weight change at 12 years in the current study (387 patients). The leveling off of weight regain between 6 years (intermediate-term) and 12 years (longterm) in the current study was also seen in the SOS study between 10 years and 15 years. 15 In a retrospective cohort of 1787 veterans (of whom 73.1% were men) who had undergone Roux-en-Y gastric bypass and were matched with 5305 participants who had not undergone such surgery, the 564 veterans who had undergone gastric bypass and were seen at the 10-year followup had a mean weight change of −28.6%, which, again, was very similar to the weight change in our study. 19 Furthermore, at 10 years, 72% of the patients who had undergone Roux-en-Y gastric bypass had maintained at least a 20% weight loss from baseline, and 40% had maintained at least a 30% weight loss, 19 which was also nearly identical to the results at year 12 in the current study. We note the emerging use of sleeve gastrectomy as an alternative to Roux-en-Y gastric bypass and a decreasing use of the adjustable gastric band procedure. However, few data are available on the long-term benefit and risk of sleeve gastrectomy.
Multiple short-term studies 2, [5] [6] [7] [8] 11, 15, 18, [20] [21] [22] [23] [24] [25] [26] [27] have shown significant remission rates, lower incidence rates, or both, of type 2 diabetes after bariatric surgery. Given the value of longer-term follow-up, our U.S. study, the SOS study, and a study with a 10-year follow-up involving 22 patients who underwent biliopancreatic diversion 26 are of interest, since these studies have followed patients for more than 5 years with respect to end points associated with type 2 diabetes. Although the remission rate of type 2 diabetes in the SOS study was 72% after 2 years, the rate fell to 36% at 10 years. 18 In comparison, the remission rates of type 2 diabetes in our study were 75% at 2 years, 62% at 6 years, and 51% at 12 years. These longer-term differences in remission between the two studies may be attributable to the exclusive use of the Roux-en-Y gastric bypass procedure in our study as compared with the primary use of vertical banded gastroplasty and the limited use of Roux-en-Y gastric bypass in the SOS study. 17, 18 In the current study, the remission rate of type 2 diabetes after Roux-en-Y gastric bypass was much higher among the patients with diabetes who had not received antidiabetic treatment at baseline than among the patients with diabetes for whom insulin had already been prescribed and was still significantly higher among the patients with diabetes who had received only oral medications at baseline than among the patients with diabetes for whom insulin had already been prescribed. Thus, it is intuitive to suggest that the more advanced the type 2 diabetes, the less the glycemic benefit from Roux-en-Y gastric bypass.
In the current study, Roux-en-Y gastric bypass resulted in a 91 to 92% lower incidence of newonset type 2 diabetes at 12 years than that among patients in the nonsurgery groups. The low incidence of type 2 diabetes may be a result of the combined effects of a reduction in insulin resistance and appropriate increases in insulin secretion after surgery. After a median follow-up of 10 years in the SOS study, the incidence of type 2 diabetes was 83% lower among all the patients who underwent surgery and 88% lower among patients who underwent Roux-en-Y gastric bypass than among patients in the control group. 22 Deaths by suicide occurred only among patients in the surgery group or among patients in nonsurgery group 1 after they underwent bariatric surgery, a finding consistent with the 2-year and 6-year follow-up results of our study. 11, 12 The possible association of suicide and bariatric surgery was reviewed across 28 studies. 28 The review showed that suicides, self-harm emergencies, or both were higher among patients who had undergone bariatric surgery than among persons in the general population, persons in control groups, and presurgical patients. [29] [30] [31] Potential risk factors for suicide after bariatric surgery included age younger than 35 years 32 ; hormonal changes; persistence of coexisting conditions; preexisting depression and other mood disorders; worsening or lack of improvement in health-related quality of life; social, sexual, and relationship issues; poor body image; and a history of maltreatment during childhood. 33 Furthermore, the reduced bioavailability of some serotonin reuptake inhibitors 1 month after gastric bypass 34 and an association between binge-eating disorder before bariatric surgery and the use of psychiatricrelated medications 35 have been reported. Whether the increase in suicides is attributable solely to bariatric surgery itself or whether any large, sustained weight loss would also be associated with an increased risk of suicide is unknown. On the basis of the results of the current study and of other reports of increased self-harm after bariatric surgery, 28, 33, [36] [37] [38] [39] [40] there is an apparent pressing, unmet need to better predict and prevent this uncommon but very serious sequela of bariatric surgery. 36, 40 In conclusion, the results from the current 12-year follow-up of a U.S.-based, long-term, prospective study of bariatric surgery indicate longterm durability of weight loss after Roux-en-Y gastric bypass. The weight increase between the 6-year and 12-year follow-up was minimal, nearcomplete prevention of new-onset type 2 diabetes was observed, and the remission rate of type 2 diabetes 12 years after surgery was 51%. Substantial improvement was also seen in systolic hypertension and lipid levels.
